Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update.
254 Results
Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update.
Biodesix announces its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.
Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person investor meetings at Cowen’s 43rd Annual Healthcare Conference.
announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York
Biodesix announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board of Directors effective January 3, 2023.
Biodesix named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine issue, Top 10 Proteomics Solutions Companies of 2022.
Biodesix announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions.
Biodesix announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.
Biodesix announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare.
Data confirms the ability of the VeriStrat® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimens.